Abstract:Background: Prolonged endoplasmic reticulum stress has been identified in various diseases. Inflammatory mediators, which have been shown to induce endoplasmic reticulum stress in several studies, have been suggested to serve as the important modulators in pain development. In this study, the authors hypothesized that the endoplasmic reticulum stress triggered by inflammatory mediators contributed to pain development. Methods: The authors used a male mouse model of bone cancer pain. The control mice were intrathecally injected with tumor necrosis factor-alpha (TNF-alpha) and lipopolysaccharide, the bone cancer pain mice were intrathecally injected with the endoplasmic reticulum stress inhibitors 4-PBA and GSK2606414. The nociceptive behaviors, endoplasmic reticulum stress markers, and inflammatory mediators were assessed. Results: Increased expression of the p-RNA-dependent protein kinase-like endoplasmic reticulum kinase and p-eukaryotic initiation factor 2 alpha were found in the spinal neurons during bone cancer pain, along with upregulation of inflammatory mediators (TNF-alpha, interleukin 1 beta, and interleukin 6). Intrathecal administration of TNF-alpha or lipopolysaccharide increased the expression of endoplasmic reticulum stress markers in control mice. Inhibition of endoplasmic reticulum stress by intrathecal administration of 4-PBA (baseline vs. 3 h: 0.34 +/- 0.16 g vs. 1.65 +/- 0.40 g in paw withdrawal mechanical threshold, 8.00 +/- 1.20 times per 2 min vs. 0.88 +/- 0.64 times per 2 min in number of spontaneous flinches, P < 0.001, n = 8) or GSK2606414 (baseline vs. 3 h: 0.37 +/- 0.08 g vs. 1.38 +/- 0.11 g in paw withdrawal mechanical threshold, 8.00 +/- 0.93 times per 2 min vs. 3.25 +/- 1.04 times per 2 min in number of spontaneous flinches, P < 0.001, n = 8) showed time- and dose-dependent antinociception. Meanwhile, decreased expression of inflammatory mediators (TNF-alpha, interleukin 1 beta, and interleukin 6), as well as decreased activation of astrocytes in the spinal cord, were found after 4-PBA or GSK2606414 treatment. Conclusions: Inhibition of inflammatory mediator-triggered endoplasmic reticulum stress in spinal neurons attenuates bone cancer pain via modulation of neuroinflammation, which suggests new approaches to pain relief.

Potential Role of Remimazolam in Alleviating Bone Cancer Pain in Mice Via Modulation of Translocator Protein in Spinal Astrocytes

Remimazolam alleviates neuropathic pain via regulating bradykinin receptor B1 and autophagy

Intrathecal Injection of Metabotropic Glutamate Receptor Subtype 3 and 5 Agonist/Antagonist Attenuates Bone Cancer Pain by Inhibition of Spinal Astrocyte Activation in a Mouse Model

MiR-135-5p Alleviates Bone Cancer Pain by Regulating Astrocyte-Mediated Neuroinflammation in Spinal Cord through JAK2/STAT3 Signaling Pathway

SIRT1 Activation Attenuates Bone Cancer Pain by Inhibiting Mglur1/5

Midazolam and ropivacaine act synergistically to inhibit bone cancer pain with different mechanisms in rats

Intrathecal Injection of the Peptide Myr-NR2B9c Attenuates Bone Cancer Pain Via Perturbing N-Methyl-D-Aspartate Receptor-PSD-95 Protein Interactions in Mice

Intrathecal Administration of SRT1720 Relieves Bone Cancer Pain by Inhibiting the CREB/CRTC1 Signalling Pathway

Melatonin attenuates bone cancer pain via the SIRT1/HMGB1 pathway

The Role of N‐methyl‐d‐aspartate Receptor Subunit NR2B in Spinal Cord in Cancer Pain

Activation of Spinal Mrgc-Gi-Nr2b-Nnos Signaling Pathway by Mas Oncogene-Related Gene C Receptor Agonist Bovine Adrenal Medulla 8-22 Attenuates Bone Cancer Pain in Mice

Inhibition of Connexin 43 and Phosphorylated NR2B in Spinal Astrocytes Attenuates Bone Cancer Pain in Mice.

Role of the CXCR4/ALK5/Smad3 Signaling Pathway in Cancer-Induced Bone Pain

Activation of Adenosine Monophosphate–activated Protein Kinase Suppresses Neuroinflammation and Ameliorates Bone Cancer Pain

Endoplasmic Reticulum Stress Contributes to Nociception Via Neuroinflammation in a Murine Bone Cancer Pain Model.

Involvement of RVM-expressed P2X7 receptor in bone cancer pain: mechanism of descending facilitation

Mas-Related G-Protein-Coupled Receptor C Agonist Bovine Adrenal Medulla 8-22 Attenuates Bone Cancer Pain in Mice

miR-199a-3p suppresses neuroinflammation by directly targeting MyD88 in a mouse model of bone cancer pain

Spinal Cannabinoid Receptor 2 Activation Reduces Hypersensitivity Associated with Bone Cancer Pain and Improves the Integrity of the Blood–spinal Cord Barrier

Relationship Between Spinal Neuronal Microrna 212 and Phosphorylation of CREB in a Mouse Model of Bone Cancer Pain

Intrathecal Injection of Selected Peptide Myr-RC-13 Attenuates Bone Cancer Pain by Inhibiting KIF17 and NR2B Expression